Van ECK Associates Corp Invests $37,000 in Abcam plc (NASDAQ:ABCM)

Van ECK Associates Corp bought a new position in Abcam plc (NASDAQ:ABCMGet Rating) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 2,501 shares of the company’s stock, valued at approximately $37,000.

Several other large investors have also added to or reduced their stakes in ABCM. Truist Financial Corp boosted its holdings in Abcam by 42.3% in the third quarter. Truist Financial Corp now owns 37,827 shares of the company’s stock valued at $567,000 after acquiring an additional 11,243 shares in the last quarter. Brown Advisory Inc. boosted its holdings in Abcam by 8.6% in the second quarter. Brown Advisory Inc. now owns 3,168,283 shares of the company’s stock valued at $45,813,000 after acquiring an additional 252,025 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in Abcam by 26.3% in the second quarter. Price T Rowe Associates Inc. MD now owns 1,553,124 shares of the company’s stock valued at $22,458,000 after acquiring an additional 323,670 shares in the last quarter. DF Dent & Co. Inc. boosted its holdings in Abcam by 9.6% in the second quarter. DF Dent & Co. Inc. now owns 816,673 shares of the company’s stock valued at $11,809,000 after acquiring an additional 71,691 shares in the last quarter. Finally, Citadel Advisors LLC boosted its holdings in Abcam by 20.4% in the second quarter. Citadel Advisors LLC now owns 130,697 shares of the company’s stock valued at $1,890,000 after acquiring an additional 22,182 shares in the last quarter. Institutional investors own 13.91% of the company’s stock.

Abcam Price Performance

Shares of Abcam stock opened at $16.36 on Friday. The business has a fifty day simple moving average of $15.98 and a two-hundred day simple moving average of $15.37. Abcam plc has a 12 month low of $12.54 and a 12 month high of $19.39.

Wall Street Analyst Weigh In

Separately, Deutsche Bank Aktiengesellschaft began coverage on shares of Abcam in a report on Tuesday, December 13th. They issued a “hold” rating on the stock.

Abcam Profile

(Get Rating)

Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. Its principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex and multiplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, miRNA kits, biochemicals, and cell signaling pathway tools.

Featured Stories

Want to see what other hedge funds are holding ABCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abcam plc (NASDAQ:ABCMGet Rating).

Institutional Ownership by Quarter for Abcam (NASDAQ:ABCM)

Receive News & Ratings for Abcam Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam and related companies with MarketBeat.com's FREE daily email newsletter.